Why Submit to SABCS?
Accepted abstracts are published in the SABCS Proceedings and featured in Clinical Cancer Research, an AACR journal.
Share your research with a multidisciplinary audience of more than 11,000 researchers, clinicians, trainees, patient advocates and industry leaders representing over 104 countries.
SABCS is recognized globally for presenting practice-changing advances across basic, translational and clinical breast cancer research.
Support is available for eligible graduate students, postdoctoral fellows and physicians-in-training presenting research at SABCS® 2026.
Presenters must opt in during the abstract submission process to be considered for available scholar awards and travel scholarships.
Key Dates
| Date | Milestone |
|---|---|
| May 1, 2026 | Call for Abstracts Opens |
| July 13, 2026 | 11:59 p.m. CT | Abstract Submission Deadline |
| Early September 2026 | Abstract Decision Notifications |
| Sept. 1-30, 2026 | 11:59 p.m. CT | Late-Breaking Abstract Submission and Edit Period |
| Oct. 30, 2026 | Abstract Titles Released Online |
| Nov. 17, 2026 | 11:59 p.m. CT | Abstract Withdrawal Deadline |
| Nov. 23, 2026 | Full Abstract Text Released Online |
Scientific Categories
SABCS welcomes abstracts spanning the full spectrum of breast cancer research, translational science and patient care.
Explore the scientific categories below to identify the best fit for your submission.
- Early Stage HER2+
- Early Stage Hormone Receptor Positive
- Early Stage Triple Negative
- Metastatic HER2+
- Metastatic Hormone Receptor Positive
- Metastatic Triple Negative
- Clinical Biomarkers and Precision Medicine
- Experimental Therapeutics and Early Phase Trials
- Clinical Trials in Progress
- Real-World Evidence
- Mechanisms of Resistance
- Molecular and Cell Tumor Biology
- Tumor Microenvironment, Immunology, and Angiogenesis
- Patient-Derived and Animal Models of Breast Cancer
- Drug Discovery, Design, and Delivery
- Cancer Survivorship and Quality of Life
- Cancer Health Disparities
- Policy, Access to Care, and Cancer Care Delivery
- Adverse Effects and Symptom Management
- Artificial Intelligence, Computational Biology, and Systems Biology
- Imaging and Early Detection
- Radiation Oncology
- Surgery
- Pathology
- Clinical Case Vignettes
Important Submission Information
- Accepted abstracts must be presented in person by a current co-author listed at the time of submission.
- Co-authors cannot be added after the July 13, 2026 deadline.
- Abstract revisions will not be permitted after 11:59 p.m. CT on July 13, 2026.
Copyright Information
All accepted abstracts, other than those that are withdrawn prior to publication and any that may have been accepted as a special late exception, will be published in the online Proceedings, as an online-only supplement in Clinical Cancer Research, and as SABCS Sessions and Poster Resources online. In addition, the San Antonio Breast Cancer Symposium currently contracts with other parties to record and transcribe oral presentations for online slide review and streaming. These resources are made available to registered attendees at no charge.
Confirmation of No Prior Publication/Presentation
Authors who submit an abstract confirm they have not previously published these data, they have not previously presented them at another scientific meeting, and that they are not planning to present or publish them prior to the dates of SABCS 2026. Preprints (draft research papers posted online before peer review) are not considered to be a prior publication if they are posted online before abstracts are submitted to SABCS.
Abstracts submitted to SABCS are confidential and embargoed until SABCS publishes the abstracts.
Certain laws may require disclosure of clinical trial data through federal and international registries within a specific amount of time following trial completion, or disclosure of clinical trial data by federal and international agencies for regulatory purposes related to drug safety and efficacy. Such disclosures will not be considered a violation of the SABCS Embargo Policy, but SABCS kindly requests advance notice by email at sabcs@uthscsa.edu.
Any other exceptions to this policy are at the discretion of SABCS leadership.
AI Guidelines
Agreement on Use of Generative AI
Generative artificial intelligence (AI), as with traditional automated and manual editing services, has the potential to improve the clarity of submitted abstracts when used to help revise or translate text written by the author. Authors may use generative AI tools in the development of abstracts submitted to the San Antonio Breast Cancer Symposium under the following conditions:
- Any use of AI in connection with the conduct of the study underlying the abstract must be described in the Methods section of the abstract.
- Any use of AI to produce new text or other material for an abstract must be disclosed in a sentence at the end of the abstract body.
- All abstract authors are fully responsible for reviewing their completed abstract (regardless of how the abstract was written) to verify the accuracy and integrity of all statements prior to submission.
- The complete editorial policy regarding the use of AI in the development of abstracts and manuscripts for publication is available on the AACR Journals website. (https://aacrjournals.org/pages/editorial-policies#ai)
SABCS 2025 Proceedings
The full SABCS® 2025 Proceedings are available in the AACR journal Clinical Cancer Research.